New Initiative to Focus Year-long Efforts into Improving Children's Vision and Eye Health
CHICAGO, Dec. 15, 2021 /PRNewswire-PRWeb/ — Prevent Blindness, the nation's oldest nonprofit eye health and safety organization, has declared 2022 the "Year of Children's Vision." The goal is to highlight and address the diverse and critical vision and eye health needs of children and to improve outcomes through advocacy, public health, education, and awareness. Common vision disorders in children include amblyopia (lazy eye), strabismus (crossed eyes), and refractive error, including myopia, hyperopia and astigmatism.
According to the recent report, "Children's Vision and Eye Health: A Snapshot of Current National Issues," from the National Center for Children's Vision and Eye Health at Prevent Blindness (NCCVEH), vision plays a critical role in children's physical, cognitive, and social development. Yet, up to one in 5 young children has an undiagnosed vision disorder. Unfortunately, uncorrected vision disorders remain common, and can impair child development, interfere with learning, reduce quality of life, and even lead to permanent vision loss.
Additionally, the annual economic costs of children's vision disorders are approximately $10 billion in the United States alone, with families shouldering a significant portion of the costs, including medical care, vision aids and devices and more.
To help address these concerns, Prevent Blindness will embark on a variety of initiatives and programs throughout the Year of Children's Vision, including but not limited to:
Provide families, caregivers, and professionals with free educational materials and resources on a variety of eye health topics including visual disorders and eye safety recommendations.
Continue efforts to inform and work with policymakers on opportunities to address children's vision and eye health as part of early childhood development, education, health equity, and public health.
Conduct a series of free webinars, hosted by the NCCVEH, including topics such as vision health of children with special needs, and workshops from the Better Vision Together community and state coalitions.
Expand the reach of the NCCVEH-convened Children's Vision Equity Alliance.
Lead efforts to promote new research into children's eye and vision health.
Launch various social media campaigns on specific children's vision topics and issues. Campaigns to include the #YOCV in posts. Followers will be asked to include the hashtag in their posts.
Conduct various programs throughout the Prevent Blindness affiliate network dedicated to advancing children's vision, including vision screening events and health fairs, Person of Vision award ceremonies, recognition of state and local advocates, and more.
"In 1908, Prevent Blindness was founded as a public health agency dedicated to saving sight in newborns. Through the decades, we've greatly expanded our mission to address a variety of children's vision issues, including the role that healthy vision plays in learning, health disparities and access to care for minority populations, and advocating for funding to support research and programs," said Jeff Todd, president and CEO of Prevent Blindness.
Added Todd, "We look forward to 2022 and the Year of Children's Vision and invite all those interested in supporting this important cause to contact us today to help us provide a brighter future for our kids."
For more information on children's vision and eye health, please visit https://preventblindness.org/. For information on partnering or sponsorship opportunities for the Year of Children's Vision, please contact Kate Desulis, Prevent Blindness Director of Development, at [email protected].
About Prevent Blindness
Founded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at preventblindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.
Sarah Hecker, Prevent Blindness, 312.363.6035, [email protected]
SOURCE Prevent Blindness
The FDA approved AbbVie Inc's (NYSE: ABBV) Rinvoq (upadacitinib; 15 mg) for active psoriatic arthritis (PsA). Like Pfizer Inc's (NYSE: PFE) approval for Xeljanz, Rinvoq's approval also covers adult patients who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. Earlier this month, the FDA slapped boxed warnings on the labels of Xeljanz, Rinvoq, and Eli Lilly And Co's (NYSE: LLY) Olumiant, flagging the risk of cardiovascular events in high-risk pat
Inovio (INO) made a big splash last year with its Covid-19 DNA vaccine candidate INO-4800. Development, however, has been slow, and the vaccine is still a while away from entering the market, should it ever get that far. In the meantime, Inovio has been working on other, less headline grabbing candidates in its pipeline. On Tuesday, Inovio provided an update from the development of the Phase 3 program for VGX-3100, indicated to treat HPV-associated cervical high-grade squamous intraepithelial le
The stock had been more than 1.5% higher, but slipped back into negative territory. Management had said the treatment might lose potency against the variant.
Omicron and new variants will dominate the Moderna stock conversation in 2022, experts said as shares yo-yoed on fresh Covid news.
Biogen’s Alzheimer’s drug Aduhelm drew fire after its FDA approval, but the company's confirmatory trial is on a quicker-than-expected timeframe.
Is AbbVie stock a buy as shares retake their key moving averages on strong third-quarter earnings? Is ABBV stock a buy right now?
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced preclinical data demonstrating the synergistic anti-leukemic effects of pelareorep combined with the chemotherapeutic agent azacitidine. The data were featured in a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, which took place from December 11-14, 2021, in Atlanta, Georgia.
"When I drive, I don't look at the rearview mirror," the AmMax Bio chairman and CEO said. "I drive forward."
Investors are always on the lookout for untapped opportunities. Looking at the case for BioCryst Pharmaceuticals (BCRX), Oppenheimer’s Justin Kim thinks that the biotech fits the bill, calling it an “underappreciated commercial-stage company with pipeline growth potential.” At the heart of Kim’s thesis lies Orladeyo, the biotech’s treatment for the prevention of hereditary angioedema (HAE) attacks, which was granted FDA approval in December 2020. Characterized by unpredictable and possibly life-
Is Pfizer stock a buy after a new Covid variant emerged that partially eludes protection from its Covid shot? Is PFE stock a buy right now?
The pandemic has taken yet another turn with the discovery of the Omicron variant. Mounting research has shown that the latest version of the virus is likely to be more contagious and make currently available vaccines less effective. And as more information comes in, Anthony Fauci, MD, chief COVID adviser to the White House, is warning fully vaccinated people that there's still one major thing they need to do to protect themselves from the latest variant.RELATED: 70 Percent of Hospitalized Omicr
(Bloomberg) — Citigroup Inc. said staffers in the New York City metropolitan area could work from home again through the holidays if they are able, citing the recent rise in Covid-19 cases in the region.Most Read from BloombergFed Doubles Taper, Signals Three 2022 Hikes in Inflation PivotCrypto Prices Go Haywire on Coinbase, CoinMarketCap.comU.K. Travelers to France Face Stricter Rules to Slow OmicronOmicron Infects 70 Times Faster But Is Less Severe, Study SaysChina’s Bubble Bursting Has Wall
GeoVax Labs Inc (NASDAQ: GOVX) initiated vaccine dosing in the Phase 2 portion of its Phase 1/2 trial of COH04S1 COVID-19 vaccine to target both the spike (S) and nucleocapsid (N) proteins. The Phase 1 portion of the trial was designed as a dose-escalation safety study in healthy adult individuals aged 18 to 55 who had not been previously infected with SARS-CoV-2. The primary objectives were to evaluate the safety, tolerability, and immunogenicity of the COH04S1 vaccine in healthy volunteers adm
Former Biden Transition COVID Advisory Board member Dr. Julie Morita joins Yahoo Finance Live to discuss Omicron as well as the demands for booster shots and vaccines. She also mentions that Americans are not out of the woods yet as we head into the holiday season.
The rapid spread of the omicron variant is the latest reminder that COVID-19 boosters may be necessary both now and in the future.
Multiple sclerosis (MS) is a disease of the central nervous system that can result in a patchwork of often confounding symptoms. Because no single test can diagnose MS, and because its symptoms can differ so staggeringly from person to person, it often flies under the radar for a long time. This is why doctors are sharing the various symptoms associated with MS—by making them known to the public, patients may be able to piece together the complicated puzzle of their diagnosis with the help of th
Sigilon Therapeutics Inc. is laying off 40 employees — 38% of its workforce — and scaling back work on its drugs for rare blood disorders.
After the untimely passing of his 5-month-old son Zen earlier this month, Nick Cannon is now sharing more intimate details about the young infant's battle with High-Grade Gliomas–a diverse group of tumors that develop on the brain and spinal cord.
All three U.S.-authorized COVID-19 vaccines appear to be significantly less protective against the newly-detected Omicron variant of the coronavirus in laboratory testing, but a booster dose likely restores most of the protection, according to a study released on Tuesday. The study from researchers at Massachusetts General Hospital (MGH), Harvard and MIT that has not yet been peer reviewed tested blood from people who received the Moderna, Johnson & Johnson and Pfizer/BioNTech vaccines against a pseudovirus engineered to resemble the Omicron variant. The researchers found "low to absent" antibody neutralization of the variant from the regular regimens of all three vaccines – two shots of the Moderna or Pfizer/BioNTech vaccines or one of J&J's single-dose vaccine.
MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe: "A Method of Immune Modulation by Modulating a Specific Gene."